Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifamycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifamycin SCHEMBL22389512 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL31715824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29355202 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL2320 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL182452 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL151824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL23370269 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29649054 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22389517 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29816867 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139178-A1 | METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION | AMYLOID SOLUTION INC. (KR) | 2024-05-02 | — | — | US | disclosed |
| EP-3888655-B1 | THERAPEUTIC COMPOSITION COMPRISING RIFAPENTINE FOR USE IN TREATING AMYLOID NEUROLOGICAL DISEASES | AMYLOID SOLUTION INC (KR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3888655-A1 | THERAPEUTIC COMPOSITION AND TREATMENT METHOD FOR AMYLOID NEUROLOGICAL DISEASES | Amyloid Solution Inc. (KR) | 2021-10-06 | — | — | EP | disclosed |
| US-20200330474-A1 | COMPOSITION AND METHOD FOR TREATMENT OF AMYLOID CRANIAL NEUROPATHY | AMYLOID SOLUTION INC. (KR) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330474-A1 | COMPOSITION AND METHOD FOR TREATMENT OF AMYLOID CRANIAL NEUROPATHY | MAPT, PSEN1, PYGB | ABCB11 3884/4885TBXA2R 3620/4885CHRM1 2023/4885 |
| US-20240139178-A1 | METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION | PSEN2, PSEN1, NEFM | ABCB11 4667/4885TBXA2R 4353/4885CHRM1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.